WO2014093230A3 - Compositions et procédés de fabrication de composés pyrimidine et pyridine ayant une activité inhibitrice de btk - Google Patents
Compositions et procédés de fabrication de composés pyrimidine et pyridine ayant une activité inhibitrice de btk Download PDFInfo
- Publication number
- WO2014093230A3 WO2014093230A3 PCT/US2013/073895 US2013073895W WO2014093230A3 WO 2014093230 A3 WO2014093230 A3 WO 2014093230A3 US 2013073895 W US2013073895 W US 2013073895W WO 2014093230 A3 WO2014093230 A3 WO 2014093230A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pyrimidine
- pyridine compounds
- compositions
- production
- methods
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/68—One oxygen atom attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne de nouveaux composés pyrimidine et pyridine, qui sont fixés à une tête à éjection, et leur fabrication et utilisation pour le traitement de maladies hyperprolifératives comprenant, mais sans s'y limiter, le cancer, le lupus, des troubles allergiques, le syndrome de Sjögren et la polyarthrite rhumatoïde. L'invention concerne également des inhibiteurs de kinase comprenant, mais sans s'y limiter, des inhibiteurs de la tyrosine kinase de Bruton.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261735186P | 2012-12-10 | 2012-12-10 | |
| US61/735,186 | 2012-12-10 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2014093230A2 WO2014093230A2 (fr) | 2014-06-19 |
| WO2014093230A3 true WO2014093230A3 (fr) | 2014-08-28 |
Family
ID=49885412
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2013/073895 Ceased WO2014093230A2 (fr) | 2012-12-10 | 2013-12-09 | Compositions et procédés de fabrication de composés pyrimidine et pyridine ayant une activité inhibitrice de btk |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2014093230A2 (fr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016258192B2 (en) | 2015-05-06 | 2021-07-29 | Leidos Biomedical Research, Inc. | K-Ras modulators |
| EP4014977A1 (fr) * | 2015-11-04 | 2022-06-22 | Merck Patent GmbH | Composés pyrimidine ayant une activité inhibitrice de la btk pour utilisation dans le traitement du cancer |
| KR102780243B1 (ko) * | 2015-11-17 | 2025-03-14 | 메르크 파텐트 게엠베하 | Btk 억제 활성을 갖는 피리미딘 및 피리딘 화합물을 사용하여 다발성 경화증을 치료하는 방법 |
| CN107641121B (zh) * | 2016-07-20 | 2021-02-19 | 上海高驰资产管理有限公司 | 一种荧光探针及其制备方法和用途 |
| AU2018255413A1 (en) | 2017-04-20 | 2019-12-05 | Leidos Biomedical Research, Inc. | K-Ras modulators |
| AR113796A1 (es) * | 2017-11-06 | 2020-06-10 | Lilly Co Eli | Compuestos inhibidores de tirosina cinasa de bruton (btk) |
| CN109824603B (zh) * | 2017-11-23 | 2021-03-12 | 浙江省化工研究院有限公司 | 一种嘧啶胺类化合物、其制备方法及应用 |
| CN108069911A (zh) * | 2017-12-14 | 2018-05-25 | 中国药科大学 | 6-氨基-2-苯基嘧啶类化合物、制备方法和医药用途 |
| US11325896B2 (en) | 2017-12-20 | 2022-05-10 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| TW202012370A (zh) * | 2018-04-18 | 2020-04-01 | 美商德洛斯股份有限公司 | 具氰基丙烯基醯胺部分之k-ras調節劑 |
| CN112250666B (zh) * | 2020-10-09 | 2022-01-14 | 广东东阳光药业有限公司 | 取代的嘧啶类化合物及其用途 |
| US11866421B2 (en) | 2021-05-31 | 2024-01-09 | Epigen Biosciences, Inc. | Pyrimidine and pyridine amine compounds and usage thereof in disease treatment |
Citations (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0658548A1 (fr) * | 1993-12-17 | 1995-06-21 | Tanabe Seiyaku Co., Ltd. | Dérivés de la benzènesulfonamide et procédé de préparation |
| WO1996029301A1 (fr) * | 1995-03-21 | 1996-09-26 | Agrevo Uk Limited | Composes fongicides |
| JPH0959160A (ja) * | 1995-06-16 | 1997-03-04 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
| WO1997044325A1 (fr) * | 1996-05-22 | 1997-11-27 | Basf Aktiengesellschaft | Derives d'acide de 2-(o-[pyrimidin-4-yl]methylenoxy)phenylacetique et leur utilisation pour lutter contre les champignons nuisibles et les parasites animaux |
| WO2005070934A1 (fr) * | 2004-01-14 | 2005-08-04 | Amgen Inc. | Diazabicycloheptanes substitues et leur utilisation comme inhibiteurs de la proteine kinase |
| US20060217417A1 (en) * | 2005-03-28 | 2006-09-28 | Boehringer Ingelheim International Gmbh | Pyridine derivatives useful as inhibitors of pkc-theta |
| WO2007084786A1 (fr) * | 2006-01-20 | 2007-07-26 | Novartis Ag | Derives de pyrimidine utilises en tant qu’inhibiteurs de kinase pi-3 |
| WO2010022725A1 (fr) * | 2008-08-27 | 2010-03-04 | Leo Pharma A/S | Dérivés de pyridine comme récepteur de vegfr-2 et inhibiteurs de la protéine tyrosine kinase |
| JP2010209277A (ja) * | 2009-03-12 | 2010-09-24 | Konica Minolta Medical & Graphic Inc | 有機圧電材料、超音波振動子および超音波探触子 |
| WO2011060440A2 (fr) * | 2009-11-16 | 2011-05-19 | The Regents Of The University Of California | Inhibiteurs de kinases |
| WO2011099764A2 (fr) * | 2010-02-09 | 2011-08-18 | Hanmi Holdings Co., Ltd. | Nouveau dérivé de la pyrimidine pour l'inhibition de la croissance des cellules cancéreuses |
| US20120208815A1 (en) * | 2007-03-01 | 2012-08-16 | Matthew Burger | Pim kinase inhibitors and methods of their use |
| WO2012158843A2 (fr) * | 2011-05-17 | 2012-11-22 | The Regents Of The University Of California | Inhibiteurs de kinase |
| WO2012170976A2 (fr) * | 2011-06-10 | 2012-12-13 | Merck Patent Gmbh | Compositions et procédés de production de composés pyrimidine et pyridine ayant une activité inhibitrice de btk |
-
2013
- 2013-12-09 WO PCT/US2013/073895 patent/WO2014093230A2/fr not_active Ceased
Patent Citations (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0658548A1 (fr) * | 1993-12-17 | 1995-06-21 | Tanabe Seiyaku Co., Ltd. | Dérivés de la benzènesulfonamide et procédé de préparation |
| WO1996029301A1 (fr) * | 1995-03-21 | 1996-09-26 | Agrevo Uk Limited | Composes fongicides |
| JPH0959160A (ja) * | 1995-06-16 | 1997-03-04 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
| WO1997044325A1 (fr) * | 1996-05-22 | 1997-11-27 | Basf Aktiengesellschaft | Derives d'acide de 2-(o-[pyrimidin-4-yl]methylenoxy)phenylacetique et leur utilisation pour lutter contre les champignons nuisibles et les parasites animaux |
| WO2005070934A1 (fr) * | 2004-01-14 | 2005-08-04 | Amgen Inc. | Diazabicycloheptanes substitues et leur utilisation comme inhibiteurs de la proteine kinase |
| US20060217417A1 (en) * | 2005-03-28 | 2006-09-28 | Boehringer Ingelheim International Gmbh | Pyridine derivatives useful as inhibitors of pkc-theta |
| WO2007084786A1 (fr) * | 2006-01-20 | 2007-07-26 | Novartis Ag | Derives de pyrimidine utilises en tant qu’inhibiteurs de kinase pi-3 |
| US20120208815A1 (en) * | 2007-03-01 | 2012-08-16 | Matthew Burger | Pim kinase inhibitors and methods of their use |
| WO2010022725A1 (fr) * | 2008-08-27 | 2010-03-04 | Leo Pharma A/S | Dérivés de pyridine comme récepteur de vegfr-2 et inhibiteurs de la protéine tyrosine kinase |
| JP2010209277A (ja) * | 2009-03-12 | 2010-09-24 | Konica Minolta Medical & Graphic Inc | 有機圧電材料、超音波振動子および超音波探触子 |
| WO2011060440A2 (fr) * | 2009-11-16 | 2011-05-19 | The Regents Of The University Of California | Inhibiteurs de kinases |
| WO2011099764A2 (fr) * | 2010-02-09 | 2011-08-18 | Hanmi Holdings Co., Ltd. | Nouveau dérivé de la pyrimidine pour l'inhibition de la croissance des cellules cancéreuses |
| WO2012158843A2 (fr) * | 2011-05-17 | 2012-11-22 | The Regents Of The University Of California | Inhibiteurs de kinase |
| WO2012170976A2 (fr) * | 2011-06-10 | 2012-12-13 | Merck Patent Gmbh | Compositions et procédés de production de composés pyrimidine et pyridine ayant une activité inhibitrice de btk |
Non-Patent Citations (12)
| Title |
|---|
| DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; CORNELL, CLIVE LEONARD ET AL: "Preparation of 2-naphthyl-3-methoxyacrylates as agrochemical fungicides and pesticides", XP002725287, retrieved from STN Database accession no. 1996:716436 * |
| DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; DENNY, WILLIAM A. ET AL: "Potential antitumor agents. 29. Quantitative structure-activity relationships for the antileukemic bisquaternary ammonium heterocycles", XP002725283, retrieved from STN Database accession no. 1979:66509 * |
| DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; NISHIKUBO, YUICHI: "Organic piezoelectric materials, ultrasonic vibrators therewith, and ultrasound probes therewith", XP002720931, retrieved from STN Database accession no. 2010:1193753 * |
| DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; PEGIADOU, S. ET AL: "The synthesis and characterization of new polymerizable pyrimidines: immobilization of the monomers onto hydrophilic graft copolymeric supports through radiation-induced copolymerization-grafting", XP002725282, retrieved from STN Database accession no. 1998:592481 * |
| DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; RACK, MICHAEL ET AL: "Preparation of .alpha.-[2-(pyrimidinyloxymethyl)phenyl]acrylates as agrochemical fungicides and pesticides", XP002725285, retrieved from STN Database accession no. 1997:776155 * |
| DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; SHULTZ, MICHAEL D. ET AL: "Optimization of the in vitro cardiac safety of hydroxamate-based Histone deacetylase inhibitors", XP002720930, retrieved from STN Database accession no. 2011:776102 * |
| DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; YAMADA, KOICHIRO ET AL: "Preparation of (N-pyrimidinyl)benzenesulfonamide endothelin antagonists", XP002725288, retrieved from STN Database accession no. 1995:890091 * |
| DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; YAMADA, KOICHIRO ET AL: "Preparation of pyrimidine derivatives as endothelin antagonists", XP002725286, retrieved from STN Database accession no. 1997:257401 * |
| DENNY, WILLIAM A. ET AL: "Potential antitumor agents. 29. Quantitative structure-activity relationships for the antileukemic bisquaternary ammonium heterocycles", JOURNAL OF MEDICINAL CHEMISTRY , 22(2), 134-50 CODEN: JMCMAR; ISSN: 0022-2623, 1979, DOI: 10.1021/JM00188A005 * |
| MI YOUNG CHA ET AL: "Synthesis and Biological Evaluation of Pyrimidine-Based Dual Inhibitors of Human Epidermal Growth Factor Receptor 1 (HER-1) and HER-2 Tyrosine Kinases", JOURNAL OF MEDICINAL CHEMISTRY, vol. 55, no. 6, 22 March 2012 (2012-03-22), pages 2846 - 2857, XP055104213, ISSN: 0022-2623, DOI: 10.1021/jm201758g * |
| PEGIADOU, S. ET AL: "The synthesis and characterization of new polymerizable pyrimidines: immobilization of the monomers onto hydrophilic graft copolymeric supports through radiation-induced copolymerization-grafting", JOURNAL OF APPLIED POLYMER SCIENCE , 70(2), 211-218 CODEN: JAPNAB; ISSN: 0021-8995, 1998, DOI: 10.1002/(SICI)1097-4628(19981010)70:2<211::AID-APP1>3.0.CO;2-X * |
| SHULTZ, MICHAEL D. ET AL: "Optimization of the in vitro cardiac safety of hydroxamate-based Histone deacetylase inhibitors", JOURNAL OF MEDICINAL CHEMISTRY , 54(13), 4752-4772 CODEN: JMCMAR; ISSN: 0022-2623, 2011, DOI: 10.1021/JM200388E * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014093230A2 (fr) | 2014-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2014093230A3 (fr) | Compositions et procédés de fabrication de composés pyrimidine et pyridine ayant une activité inhibitrice de btk | |
| WO2012170976A3 (fr) | Compositions et procédés de production de composés pyrimidine et pyridine ayant une activité inhibitrice de btk | |
| MX368042B (es) | COMPUESTOS ÚTILES COMO INHIBIDORES DE CINASA RELACIONADA CON ATAXIA TELANGIECTASIA MUTADA Y Rad3 (ATR). | |
| IN2014KN02410A (fr) | ||
| SA515360007B1 (ar) | مركبات عطرية غير متجانسة كمثبطات بروتونز تيروسين كيناز ( btk) | |
| WO2015039612A8 (fr) | Composé inhibiteur d'activités de kinase de btk et/ou de jak3 | |
| WO2014145028A3 (fr) | N-acyl-n'-(pyridin-2-yl)urées et analogues montrant des activités anticancéreuses et antiprolifératives | |
| HK1214823A1 (zh) | 作為jak抑制劑的三環稠合噻吩衍生物 | |
| HK1246286A1 (zh) | Lrrk2抑制剂及其制备和使用方法 | |
| MY199511A (en) | Novel condensed pyrimidine compound or salt thereof | |
| WO2014143242A8 (fr) | Composés utiles en tant qu'inhibiteurs de la kinase atr | |
| PH12015501965A1 (en) | Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor | |
| WO2014145029A3 (fr) | Urées n-acyl-n (pyridin-2-yl) et analogues présentant des activités anticancéreuses et antiprolifératives | |
| WO2011143423A3 (fr) | Composés utilisables en tant qu'inhibiteurs de la kinase atr | |
| HK1199643A1 (en) | Oxazolidin- 2 -one compounds and uses thereof as pi3ks inhibitors | |
| MX380147B (es) | Formas de dosificacion de ruxolitinib de liberacion sostenida. | |
| WO2012162254A8 (fr) | Inhibiteurs de l'activité lrrk2 kinase | |
| WO2013151665A3 (fr) | Polynucléotides modifiés destinés à la production de protéines associées à une maladie humaine | |
| HK1216425A1 (zh) | 基於2,3-二氢咪唑并[1,2-c]嘧啶-5(1h)-酮的脂蛋白相关磷脂酶a2(lp-pla2)抑制剂 | |
| TN2017000144A1 (en) | 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors | |
| TN2017000415A1 (en) | Heterocyclylmethyl-thienouracile as antagonists of the adenosine-a2b-receptor | |
| TW201613896A (en) | Novel 2,5-substituted pyrimidines | |
| NZ702254A (en) | 5-amino[1,4]thiazines as bace 1 inhibitors | |
| HK1201523A1 (en) | Heterocyclic carboxamides useful as inhibitors of phosphodiesterase type 10a | |
| IN2012DN02675A (fr) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13814709 Country of ref document: EP Kind code of ref document: A2 |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 13814709 Country of ref document: EP Kind code of ref document: A2 |